TMDX
NASDAQTransMedics Group Inc.
News · 26 weeks44-29%
2026-03-012026-08-23
Mix1590d
- Insider5(33%)
- Other4(27%)
- SEC Filings3(20%)
- Earnings2(13%)
- Analyst1(7%)
Latest news
25 items- INSIDERDirector Tobin James R gifted 18,000 shares (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- SECSEC Form 10-Q filed by TransMedics Group Inc.10-Q - TransMedics Group, Inc. (0001756262) (Filer)
- SECTransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TransMedics Group, Inc. (0001756262) (Filer)
- PRTransMedics Reports Second Quarter 2026 Financial ResultsANDOVER, Mass., Aug. 4, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2026. Recent HighlightsTotal revenue of $189.9 million in the second quarter of 2026, a 21% increase compared to the second quarter of 2025Product revenue of $111.2 million, up 16% and Service revenue of $78.8 million, up 29%Net income of $14.7 million or $0.41 per fully diluted share in the second quarter of 2026Adjusted net income o
- PRTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)ANDOVER, Mass., Aug. 3, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 29, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 18,762 shares of its common stock and an aggregate of 12,414 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4)
- PRTransMedics to Present at the Canaccord Genuity 46th Annual Growth ConferenceANDOVER, Mass., July 28, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. The TransMedics management team will present beginning at 2:00 p.m. ET/ 1:00 p.m. CT A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Compan
- ANALYSTUBS initiated coverage on TransMedics Group with a new price targetUBS initiated coverage of TransMedics Group with a rating of Neutral and set a new price target of $80.00
- PRTransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026ANDOVER, Mass., July 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2026 after market close on Tuesday, August 4, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international call
- INSIDEROfficer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERChief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERPresident & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- PRTransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbHStrategic investment in Germany-based PAD Aviation, a premier European private aviation operator, lays the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across EuropeANDOVER, Mass., July 6, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the closing of its strategic investment in PAD Aviation, a premier Germany-based private aviation operator. The investment in PAD Aviation is a critical step forward fo
- INSIDERDirector Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- SECSEC Form 144 filed by TransMedics Group Inc.144 - TransMedics Group, Inc. (0001756262) (Subject)
- SECSEC Form SD filed by TransMedics Group Inc.SD - TransMedics Group, Inc. (0001756262) (Filer)
- INSIDERDirector Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDEROfficer Forsyth Matthew S. was granted 15,409 shares (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- SECSEC Form 8-K filed by TransMedics Group Inc.8-K - TransMedics Group, Inc. (0001756262) (Filer)
- PRTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 19, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 37,367 shares of its common stock and an aggregate of 24,848 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants included stock options to purchase 23,171 shares of TransMedics' common stock and 15,409 restricted stock units granted to Matthew S. Forsyth, the Co
TMDX FAQ
7 questionsWhat does TransMedics Group Inc. do?
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state...Where does TMDX stock trade?
TransMedics Group Inc. (TMDX) is listed on NASDAQ.What sector and industry is TMDX in?
TransMedics Group Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did TransMedics Group Inc. go public?
TransMedics Group Inc. (TMDX) completed its IPO in 2019.What are analysts saying about TMDX?
TransMedics Group Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral on 2026-07-28.What companies are similar to TMDX?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare TMDX side-by-side with any of them on Quantisnow.How can I track TMDX on Quantisnow?
Quantisnow aggregates TransMedics Group Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TMDX to receive live email and push alerts on every new disclosure.